How long does gosatuzumab treatment extend life?

Gosatuzumab/Trodelvy (Trodelvy) is an antibody-drug conjugate targeting the Trop-2 target. It is commonly used to treat patients with metastatic triple-negative breast cancer who have failed multiple lines of treatment, as well as some patients with hormone receptor-positive but HER2-negative advanced breast cancer. As an ADC drug, it combines the targeted antibody with the potent cytotoxic drug SN-38 through a linker to achieve precise delivery and local killing of tumor cells. This mechanism significantly improves the specificity of the therapeutic effect while relatively reducing the widespread toxicity to normal tissues, making it a breakthrough solution in the treatment of complex tumors.

Regarding the survival benefit that gosatuzumab treatment can bring, a number of studies have shown that it has significant advantages in extending progression-free survival (PFS) and overall survival (OS). Although the specific life extension time is affected by many factors, such as tumor type, disease stage, patient drug resistance, systemic condition, etc., overall, gosatuzumab has extended survival by 3 to 6 months or even longer for some patients. More importantly, this extension is not just reflected in the length of time, but also includes significant improvements in quality of life, such as reduction in tumor burden, pain relief, recovery of mobility, etc., which are particularly valuable for patients with advanced cancer.

It should be noted that gosatuzumab is usually used for patients with advanced disease or extremely limited treatment options. Therefore, its treatment goal is "life extension and disease control" rather than a complete cure. Many patients who have failed multiple lines of treatment can obtain a valuable remission period through gosatuzumab, prolonging their lives and gaining a waiting window for new treatments. In addition, gosatuzumab is currently exploring a variety of new indications, including bladder cancer, small cell lung cancer, etc., and future survival data are expected to be further optimized.

Reference materials:https://www.trodelvy.com/